3PEA International, Inc. (Paysign, Inc.) - 10-K Summary
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended December 31, 2010. The registrant, 3PEA International, Inc. (referred to in the prompt as Paysign, Inc.), is a payment solutions company focused on proprietary transaction processing for healthcare and financial applications, specifically prepaid debit cards (stored value cards). The primary market is pharmaceutical marketing (drug sampling), with secondary focus on survey rewards. The company is classified as a smaller reporting company and a shell company status was denied. The auditor has issued a going concern opinion due to recurring losses and substantial doubt about the company's ability to continue operations without additional capital.
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 | 2009 |
|---|---|---|
| Revenues | $4,347,831 | $4,201,075 |
| Cost of Revenues | $3,608,116 | $3,660,598 |
| Gross Profit | $739,715 | $540,477 |
| Gross Margin | 17.0% | 12.9% |
| Operating Income (Loss) | $81,907 | ($479,495) |
| Net Loss | ($8,292) | ($96,140) |
| Cash from Operating Activities | $64,325 | ($273,826) |
| Cash and Cash Equivalents (Unrestricted) | $42,214 | $2,903 |
| Restricted Cash | $4,409,068 | $3,434,673 |
| Total Current Liabilities | $9,331,319 | $6,807,496 |
| Working Capital Deficit | ($3,235,150) | N/A |
Note: Working capital deficit excludes restricted cash which is offset by customer card funding liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by $146,756 (3.5%) driven by increased processing of program cards (717,000 transactions in 2010 vs. 674,000 in 2009).
- Profitability Improvement: The company moved from an operating loss of $479,495 in 2009 to an operating income of $81,907 in 2010. This was primarily due to a $328,783 reduction in Selling, General, and Administrative (SG&A) expenses resulting from cost-cutting measures (reduced consultants and employee compensation).
- One-Time Items: The 2009 results included a $527,673 gain on forgiveness of indebtedness related to a subsidiary's bankruptcy, which was not present in 2010. Without this, 2009 would have shown a significantly larger loss.
- Liquidity: Unrestricted cash increased from $2,903 to $42,214. However, the company faces a significant working capital deficit of approximately $3.2 million, with $2.4 million in accounts payable and accrued liabilities (some past due) and $2.5 million in current notes payable.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects revenues to remain flat or trend downward in the short term due to declining average program sizes caused by economic conditions. Long-term revenue growth is expected as the economy improves and new products are rolled out.
- Capital Needs: The company is actively seeking additional capital through a private placement of equity or debt to fund expansion and repay indebtedness. There is no assurance of success. The company plans to renegotiate debt terms or convert debt to equity.
- Going Concern: The auditor's report explicitly states substantial doubt about the company's ability to continue as a going concern. The financial statements do not include adjustments that might be necessary if the company cannot continue operations.
- Risks:
- Regulatory: Subject to extensive regulation including anti-money laundering (BSA/PATRIOT Act), HIPAA, and state money transmission laws. Non-compliance could result in fines or license revocation.
- Concentration: Heavy reliance on the pharmaceutical sampling market and a single card-issuing bank (Monterey County Bank).
- Competition: Intense competition from larger firms (e.g., McKesson, Emdeon) with greater resources.
- Stock Liquidity: Common stock trades on Pink Sheets and is subject to "penny stock" rules, limiting marketability.
Investor Verification Checklist
- Debt Conversion Status: Verify if the company has successfully converted the $2.5 million in current notes payable and past-due accounts payable into equity, as this is critical to resolving the working capital deficit.
- Capital Raise Progress: Confirm the status of the private placement with Colorado Financial Service Corporation intended to raise $5 million.
- Banking Relationship: Assess the stability of the relationship with Monterey County Bank, the sole card issuer, and the terms of the agreement expiring in 2013.
- Pharmaceutical Client Retention: Verify if the decline in average program size is a temporary economic effect or a structural shift in client marketing budgets.
- Legal Proceedings: Monitor for any legal action from creditors regarding the past-due accounts payable, which could jeopardize operations.